UNSPSC 51333411: Fluprazine

This classification denotes a serotonin agonist with the molecular formula C14H19F3N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 713BBL6840, chemically known as urea, (2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)- but generally known as fluprazine, which bears US NIH Compound Identifier 71153. European Medicines Agency schedules Fluprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07734MIG. The term FLUPRAZINE is an International Non-Proprietary Name.

UNSPSC 51333411 Fluprazine is a Commodity code that in state and local procurement activity covers pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and over-the-counter medications supplied through wholesale distribution channels and direct-to-manufacturer programs. State and local governments actually buying under this code procure pharmaceutical inventories for community health initiatives, pharmacy benefit programs, and multi-jurisdictional cooperative purchasing networks. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances that aggregate demand across multiple states and municipalities. The procurement model varies from straightforward inventory purchasing with quarterly deliveries to exploratory market-intelligence gatherings that precede formal competitive solicitations for pharmacy benefit innovation.

Activity under the code spans Florida, Texas, and Minnesota, with evidence of multi-state cooperative purchasing vehicles. Recent solicitations include Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a response deadline of July 26, 2023 — a two-year contract with one-year renewal option and potential FEMA funding; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, gathering vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, posted January 20, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals due March 26, 2026, and contract effectiveness July 1, 2026, weighted 75 percent on price competitiveness and requiring cGMP and Drug Supply Chain Security Act compliance.